Kymera Therapeutics, Inc. (KYMR) reported a first-quarter 2025 loss of 82 cents per share, narrower than the Zacks Consensus Estimate of a loss of 92 cents. In the year-ago quarter, Kymera reported a loss of 69 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The year-over-year deterioration was due to higher R&D expenses.Collaboration revenues totaled $22.1 million, which beat the Zacks Consensus Estimate of $10 million.In the year-ago quarter, Kymera earned collabo ...

Kymera Therapeutics (KYMR) Q1 2025 Earnings Call May 09, 2025 10:00 AM ET Company Participants Justine Koenigsberg - VP - Investor RelationsNello Mainolfi - Founder, President & CEOJared Gollob - Chief Medical OfficerVeronica Campbell - Senior Director - ImmunologyYvonne Kumi - VP - Senior Quantitative AnalyticsSudan Loganathan - Managing DirectorNishant Jadav - Managing DirectorYifan Xu - Senior Associate - Biotechnology Equity Research Conference Call Participants Jeet Mukherjee - AnalystMarc Frahm - Biot ...

Kymera Therapeutics (KYMR) Q1 2025 Earnings Call May 09, 2025 10:00 AM ET Speaker0 Good morning, and welcome to Chimera's immunology innovation day, our virtual event to introduce our next immunology program, IRAV five. I'm Justine Koenigsberg, Chimera's head of investor relations. Please note that we are hosting today's event in lieu of our regularly scheduled quarterly update call. However, we have reported our results and filed our 10 Q this morning. For additional details on our Q1 results, please refer ...

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.69 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.87%. A quarter ago, it was expected that this company would post a loss of $0.76 per share when it actually produced a loss of $0.88, delivering a surprise of -15.79%.Over the last four quarters, the company h ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) De ...

Exhibit 99.1 Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical tria ...

IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activ ...

Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical trial in early 2026 KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD ongoing, led by partner Sanofi; Kymera ac ...

For more information, please visit the Kymera website at https://www.kymeratx.com/ or follow Kymera on X (@KymeraTx) and LinkedIn (Kymera Therapeutics). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on X and LinkedIn. The information that Kymera posts on its website or on X ...

Core Insights - Kymera Therapeutics experienced a nearly 23% increase in share price this week, distinguishing itself in the volatile biotech sector due to positive announcements from the company [1] Company Developments - Kymera has initiated dosing in a phase 1b clinical trial for its investigational drug KT-621, which targets severe atopic dermatitis (eczema) [2][3] - The company expects to report data from the KT-621 trial in the fourth quarter of this year [3] - CEO Nello Mainolfi emphasized the significance of KT-621's advancement, highlighting the potential of their technology to transform treatment for complex immuno-inflammatory diseases through oral medications [4] Future Prospects - Kymera plans to reveal a new oral immunology program during its first-quarter earnings report, focusing on a high-value undrugged target for multiple autoimmune and rheumatic diseases [4] - The ongoing development of KT-621 is seen as a promising revenue opportunity for the company, given the commonality of atopic dermatitis [5]